Abstract
Pentoxifylline, a methyl xanthine derivative with hemorheologic properties, has been used in the treatment of peripheral and cerebrovascular occlusive diseases. To assess its effect in myocardial ischemia, 20 patients with previous myocardial infarction and silent ischemia at exercise were randomized to receive pentoxifylline 1.2 gm/day or placebo during a 3-month double-blind trial. There were no differences in age, body mass index, or risk factors between groups. At the end of the study, patients in the placebo group showed no changes in physical work capacity or ST segment depression. In contrast, patients in the pentoxifylline group showed a slight but significant increase in physical work capacity (+0.24 ± 0.07 watts/kg; P < 0.01) and a decrease in both maximal exercise-induced ST segment depression (−0.80 ± 0.18 mm; P < 0.01) and at the ninth minute of recovery (−0.38 ± 0.13 mm; P < 0.05). The drug was generally well tolerated. We conclude that pentoxifylline diminishes exercise-induced electrocardiographic changes of myocardial ischemia and improves physical work capacity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
